Evaluation of Human Metabolism and Hepatotoxicity Using Human Hepatocyte Chimeric Mice
First written in FY2016. 20 of 21 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The Group provides contract testing services and sells PXB mouse-related products, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the business of providing contract testing services and selling related products mainly in the United States, using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2024-Q3RestatedAnnual report
「The Group provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes, mainly in the United States. - FY2024-Q2RestatedAnnual report
「The Group provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes, mainly in the United States. - FY2023RestatedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Reconfirms the description of providing services mainly in the preclinical field using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2023-Q3RestatedAnnual report
「The Company provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services mainly in the United States using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2023-Q2RestatedAnnual report
「The Company provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services mainly in the United States using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2023-Q1RestatedAnnual report
「The Company provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services mainly in the United States using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2022-Q1RestatedAnnual report
「The Company provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes, mainly in the United States. - FY2021-Q2RestatedAnnual report
「The Company provides contract testing services, primarily in the United States, where the world's leading pharmaceutical companies have research and development facilities, using human hepatocyte chimeric mice in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice.」
Reconfirms the description of providing contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes, primarily in the United States. - FY2021-Q1RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2020RestatedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Reconfirms the description of providing services mainly in the preclinical field using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2020-Q3RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2020-Q2RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2019RestatedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Reconfirms the description of providing services mainly in the preclinical field using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2019-Q3RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2018RestatedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Reconfirms the description of providing preclinical drug development services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2018-Q3RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice in which more than 70% of the mouse's hepatocytes are replaced with human hepatocytes. - FY2018-Q2RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2018-Q1RestatedAnnual report
「The Group provides contract testing services using human hepatocyte chimeric mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes, marketed under the Company's product name PXB mice,」
Continues to describe contract testing services using PXB mice characterized by the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes. - FY2017RestatedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Reiterates the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes and the provision of services in the preclinical field. - FY2016First statedAnnual report
「The Company has technology for producing PXB mice, in which more than 70% of a mouse's liver is replaced with human hepatocytes. Using these human hepatocyte chimeric mice, marketed under the product name PXB mice, the Company provides various services mainly in the preclinical phase of drug discovery and development.」
Identifies the replacement of more than 70% of the mouse's hepatocytes with human hepatocytes as a technological feature.